【和誉-B(02256.HK):和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌

智通财经
26 Jun
【和誉-B(02256.HK):和誉医药将在2025年ESMO GI会议汇报依帕戈替尼与阿替利珠单抗联用治疗晚期肝细胞癌的最新2期临床试验数据】智通财经APP讯,和誉-B(02256.HK)发布公告,2025年6月26日,上海和誉生物医药科技有限公司(“和誉医药”)宣布将在2025 年欧洲肿瘤内科学会胃肠道肿瘤大会(“2025年ESMO GI会议”)上汇报依帕戈替尼(Irpagratinib/ABSK-011)与阿替利珠单抗联用治疗晚期肝细胞癌(“HCC”)患者的最新2期临床试验数据。2025年ESMO GI会议将于2025年7月2日至2025年7月 5日(当地时间)在西班牙巴塞罗那举行。本次口头汇报显示,依帕戈替尼与阿替利珠单抗联合治疗方案在未接受治疗及既往接受过治疗的FGF19过表达HCC患者中,均展现出良好的安全性与显着的疗效。依帕戈替尼联用显示达到客观缓解率(“ORR”)≥50%,中位无进展生存期(“PFS”)≥7个月。这些结果进一步证明了依帕戈替尼在既往接受过治疗和未接受治疗情况下的临床益处,为晚期HCC患者带来了新的希望。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10